Related references
Note: Only part of the references are listed.Dengue vaccine: hypotheses to understand CYD-TDV-induced protection
Bruno Guy et al.
NATURE REVIEWS MICROBIOLOGY (2016)
The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model
Beth D. Kirkpatrick et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries
Maira Aguiar et al.
PLOS NEGLECTED TROPICAL DISEASES (2016)
Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity
Kuan Rong Chan et al.
NATURE MICROBIOLOGY (2016)
A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico
Kristen Bauer et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2015)
Fc receptors in antibody-dependent enhancement of viral infections
Adam Taylor et al.
IMMUNOLOGICAL REVIEWS (2015)
Human CD8+ T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets
Daniela Weiskopf et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial
Sarah L. George et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults
Beth D. Kirkpatrick et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
Luis Villar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus
Moritz U. G. Kraemer et al.
ELIFE (2015)
The Human CD8(+) T Cell Responses Induced by a Live Attenuated Tetravalent Dengue Vaccine Are Directed against Highly Conserved Epitopes
Daniela Weiskopf et al.
JOURNAL OF VIROLOGY (2015)
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
Maria Rosario Capeding et al.
LANCET (2014)
T-cell immunity to infection with dengue virus in humans
Daniela Weiskopf et al.
FRONTIERS IN IMMUNOLOGY (2014)
The Dengue Human Challenge Model: Has the Time Come to Accept This Challenge?
Anna P. Durbin et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial
Anna P. Durbin et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Reduced Risk of Disease During Postsecondary Dengue Virus Infections
Sandra Olkowski et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
The global distribution and burden of dengue
Samir Bhatt et al.
NATURE (2013)
Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells
Daniela Weiskopf et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
Arunee Sabchareon et al.
LANCET (2012)
CURRENT CONCEPTS Dengue
Cameron P. Simmons et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans
Ming Qiao et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine
Anna P. Durbin et al.
VACCINE (2011)
Best Practices in Dengue Surveillance: A Report from the Asia-Pacific and Americas Dengue Prevention Boards
Mark E. Beatty et al.
PLOS NEGLECTED TROPICAL DISEASES (2010)
The live attenuated dengue serotype 1 vaccine rDEN1Δ30 is safe and highly immunogenic in healthy adult volunteers
Anna P. Durbin et al.
HUMAN VACCINES (2006)
Development of a live attenuated dengue virus vaccine using reverse genetics
JE Blaney et al.
VIRAL IMMUNOLOGY (2006)
rDEN4Δ30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers
AP Durbin et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections
DH Libraty et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region
AP Durbin et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2001)
Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity
DW Vaughn et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Share Paper
